<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224028</url>
  </required_header>
  <id_info>
    <org_study_id>PRGNS-10-01-KOR</org_study_id>
    <nct_id>NCT01224028</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients</brief_title>
  <official_title>Double-blind, Randomized Placebo-controlled Clinical Trial for the Efficacy and Safety of a Calcineurin Inhibitor, Tacrolimus(Prograf Cap®) in Patients With Non-nephrotic Albuminuric, Normotensive IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate efficacy and safety of tacrolimus in the patients with
      non-nephrotic albuminuric, normotensive IgA nephropathy after 16 week treatment with
      tacrolimus (Prograf) or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline UACR to mean value of UACR measured on week 12 and week 16 (UACR: Urine Albumin Creatinine Ratio)</measure>
    <time_frame>Week 0, week 12 and week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving more than 30% reduction of UACR level from baseline</measure>
    <time_frame>Week 0 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving more than 50% reduction of UACR level from baseline</measure>
    <time_frame>Week 0 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving more than 0.2 reduction of UACR level</measure>
    <time_frame>Week 0 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite event rate achieving less than 0.2 or 50% reduction of UACR level</measure>
    <time_frame>Week 0 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of UACR measured between before the study and each visit</measure>
    <time_frame>Week 0, week 4, week 8, week 12 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events according to subject's self-assessment, vital signs, investigator's assessment and labo-tests</measure>
    <time_frame>Through week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with IgA nephropathy confirmed by renal biopsy

          -  Serum creatinine measurement ≤1.5mg/ml or MDRD estimated GFR ≥ 45ml/min/1.73m2 (MDRD:
             Modification of Diet in Renal Disorder)

          -  UACR level between 0.3 and 3.0

          -  Blood pressure measurements &lt; 130/80mmHg

        Exclusion Criteria:

          -  Use of immunosuppressants for more than two weeks within last one month

          -  Concomitant use of ACE inhibitor, ARB, steroids or immunosuppressant, NDHP-CCB,
             diuretics, omega-3 fatty acids and its analogue &amp; additional dietary to treat igA
             nephropathy (ACE: Angiotensin Converting Enzyme, ARB: Angiotensin Receptor Blocker,
             NDHP-CCB: Non-dihydropyridine-type Calcium Channel Blocker

          -  Pregnant or breast-feeding patients. Patients who plan to bear children or breast-feed
             during the study and within 6 month after completion of study

          -  Hypersensitivity to the investigational drug or macrolide agents

          -  Use of potassium-sparing diuretics

          -  Persistence of liver function abnormality more than 1 month or presence of acute
             active hepatitis

          -  Other investigational drug within last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140545 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>August 20, 2014</last_update_submitted>
  <last_update_submitted_qc>August 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>Calcinurin inhibitor</keyword>
  <keyword>Albuminurea</keyword>
  <keyword>Proteinurea</keyword>
  <keyword>FK506</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

